Isoproterenol Enhances Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Embryonic Kidney Cells through Death Receptor 5 up-Regulation.
- Author:
Young Woo EOM
1
;
Ha Yun JUNG
;
Ji Eun OH
;
Jun Won LEE
;
Min Soo AHN
;
Young Jin YOUN
;
Sung Gyun AHN
;
Jang Young KIM
;
Seung Hwan LEE
;
Junghan YOON
;
Byung Su YOO
Author Information
- Publication Type:Original Article
- Keywords: Isoproterenol; TNF-related apoptosis-inducing ligand; Apoptosis; Death receptor 5
- MeSH: Apoptosis*; Cell Death; Cell Survival; Fibrosis; Fluorescein; HEK293 Cells; Humans*; Hypertrophy; Immunoblotting; Isoproterenol*; Kidney*; Microscopy; Mortality; Necrosis*; Receptors, Adrenergic; Receptors, TNF-Related Apoptosis-Inducing Ligand*; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation*
- From:Korean Circulation Journal 2016;46(1):93-98
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND AND OBJECTIVES: Chronic impairment of beta-adrenergic receptor signaling increases cardiac apoptosis, hypertrophy and fibrosis. The aim of this study was to investigate whether isoproterenol (ISO), an agonist of the adrenergic receptor, can enhance tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human embryonic kidney (HEK) 293 cells. MATERIALS AND METHODS: HEK 293 cells were treated with ISO and/or TRAIL for 24 hours. Cell viability was evaluated by microscopy and an established viability assay, and apoptotic cell death was analyzed by staining with fluorescein isothiocynate-annexin-V/propidium iodide (PI) and caspase activation. To confirm the mechanism of cell death induced by co-treatment with ISO and TRAIL, expression of TRAIL receptor 2 (death receptor 5, DR5) was evaluated by immunoblotting. RESULTS: Although ISO or TRAIL treatment decreased HEK 293 cell viability by 13% and 17%, respectively, co-treatment with ISO and TRAIL resulted in a markedly higher death rate of 35% after 24 hours. Increases were evident in early apoptotic cells (i.e., annexin-V positive/PI negative; 19.4%), late apoptotic cells (i.e., annexin-V positive/PI positive; 6.3%) and dead cells (i.e., annexin-V negative/PI positive; 1.1%) when cells were co-treated with ISO and TRAIL, compared to cells treated with either ISO or TRAIL. In addition, marked increases of cleaved cas-3, cleaved poly (adenosine diphosphate-ribose) polymerase and DR5 were observed in HEK 293 cells co-treated with ISO and TRAIL. CONCLUSION: Treatments combining ISO with TRAIL may be responsible for death of HEK 293 cells through DR5 up-regulation. Activation of adrenergic receptors is responsible for the synergistic cell death observed with TRAIL.
